Your browser doesn't support javascript.
Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in a Georgia School District-United States, December 2020-January 2021.
Gettings, Jenna R; Gold, Jeremy A W; Kimball, Anne; Forsberg, Kaitlin; Scott, Colleen; Uehara, Anna; Tong, Suxiang; Hast, Marisa; Swanson, Megan R; Morris, Elana; Oraka, Emeka; Almendares, Olivia; Thomas, Ebony S; Mehari, Lemlem; McCloud, Jazmyn; Roberts, Gurleen; Crosby, Deanna; Balajee, Abirami; Burnett, Eleanor; Chancey, Rebecca J; Cook, Peter; Donadel, Morgane; Espinosa, Catherine; Evans, Mary E; Fleming-Dutra, Katherine E; Forero, Catalina; Kukielka, Esther A; Li, Yan; Marcet, Paula L; Mitruka, Kiren; Nakayama, Jasmine Y; Nakazawa, Yoshinori; O'Hegarty, Michelle; Pratt, Caroline; Rice, Marion E; Rodriguez Stewart, Roxana M; Sabogal, Raquel; Sanchez, Emanny; Velasco-Villa, Andres; Weng, Mark K; Zhang, Jing; Rivera, Grant; Parrott, Tonia; Franklin, Rachel; Memark, Janet; Drenzek, Cherie; Hall, Aron J; Kirking, Hannah L; Tate, Jacqueline E; Vallabhaneni, Snigdha.
  • Gettings JR; Georgia Department of Public Health, Atlanta, Georgia, USA.
  • Gold JAW; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kimball A; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Forsberg K; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Scott C; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Uehara A; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Tong S; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Hast M; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Swanson MR; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Morris E; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Oraka E; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Almendares O; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Thomas ES; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mehari L; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • McCloud J; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Roberts G; General Dynamics Information Technology, Falls Church, Virginia, USA.
  • Crosby D; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Balajee A; Georgia Department of Public Health, Atlanta, Georgia, USA.
  • Burnett E; Cobb and Douglas Public Health, Marietta, Georgia, USA.
  • Chancey RJ; Cobb and Douglas Public Health, Marietta, Georgia, USA.
  • Cook P; Cobb and Douglas Public Health, Marietta, Georgia, USA.
  • Donadel M; Cobb and Douglas Public Health, Marietta, Georgia, USA.
  • Espinosa C; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Evans ME; Maximus Federal, Reston, Virginia, USA.
  • Fleming-Dutra KE; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Forero C; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kukielka EA; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Li Y; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Marcet PL; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mitruka K; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Nakayama JY; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Nakazawa Y; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • O'Hegarty M; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Pratt C; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rice ME; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rodriguez Stewart RM; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Sabogal R; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Sanchez E; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Velasco-Villa A; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Weng MK; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Zhang J; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rivera G; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Parrott T; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Franklin R; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Memark J; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Drenzek C; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Hall AJ; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kirking HL; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Tate JE; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Vallabhaneni S; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Infect Dis ; 74(2): 319-326, 2022 01 29.
Article in English | MEDLINE | ID: covidwho-1662107
ABSTRACT

BACKGROUND:

To inform prevention strategies, we assessed the extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and settings in which transmission occurred in a Georgia public school district.

METHODS:

During 1 December 2020-22 January 2021, SARS-CoV-2-infected index cases and their close contacts in schools were identified by school and public health officials. For in-school contacts, we assessed symptoms and offered SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) testing; performed epidemiologic investigations and whole-genome sequencing to identify in-school transmission; and calculated secondary attack rate (SAR) by school setting (eg, sports, elementary school classroom), index case role (ie, staff, student), and index case symptomatic status.

RESULTS:

We identified 86 index cases and 1119 contacts, 688 (61.5%) of whom received testing. Fifty-nine of 679 (8.7%) contacts tested positive; 15 of 86 (17.4%) index cases resulted in ≥2 positive contacts. Among 55 persons testing positive with available symptom data, 31 (56.4%) were asymptomatic. Highest SARs were in indoor, high-contact sports settings (23.8% [95% confidence interval {CI}, 12.7%-33.3%]), staff meetings/lunches (18.2% [95% CI, 4.5%-31.8%]), and elementary school classrooms (9.5% [95% CI, 6.5%-12.5%]). The SAR was higher for staff (13.1% [95% CI, 9.0%-17.2%]) vs student index cases (5.8% [95% CI, 3.6%-8.0%]) and for symptomatic (10.9% [95% CI, 8.1%-13.9%]) vs asymptomatic index cases (3.0% [95% CI, 1.0%-5.5%]).

CONCLUSIONS:

Indoor sports may pose a risk to the safe operation of in-person learning. Preventing infection in staff members, through measures that include coronavirus disease 2019 vaccination, is critical to reducing in-school transmission. Because many positive contacts were asymptomatic, contact tracing should be paired with testing, regardless of symptoms.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid